Valeant, Pershing Trying To Hide Behind SEC, Investors Say
By Jon Hill ( July 5, 2017, 8:04 PM EDT) -- Investors behind a class action accusing hedge fund Pershing Square and Valeant Pharmaceuticals of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. have told a California federal court that the two firms are wrongly trying to use the U.S. Securities and Exchange Commission as a shield....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.